Delcath Systems, Inc. (NASDAQ:DCTH) saw unusually-high trading volume on Wednesday . Approximately 147,629,302 shares changed hands during mid-day trading, an increase of 40% from the previous session’s volume of 105,731,000 shares.The stock last traded at $0.12 and had previously closed at $0.10.

The firm’s 50-day moving average is $0.12 and its 200-day moving average is $0.10. The stock’s market cap is $51.57 million.

A number of hedge funds have recently bought and sold shares of DCTH. Renaissance Technologies LLC lifted its stake in Delcath Systems by 167.3% in the 4th quarter. Renaissance Technologies LLC now owns 160,128 shares of the medical device company’s stock valued at $147,000 after buying an additional 100,214 shares in the last quarter. Vanguard Group Inc. lifted its stake in Delcath Systems by 207.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,285,679 shares of the medical device company’s stock valued at $253,000 after buying an additional 866,838 shares in the last quarter. Finally, Virtu KCG Holdings LLC lifted its stake in Delcath Systems by 72.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 1,518,724 shares of the medical device company’s stock valued at $299,000 after buying an additional 637,689 shares in the last quarter. 7.97% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/06/delcath-systems-inc-dcth-sees-unusually-high-trading-volume-2.html.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).